Syndromes of Thrombosis and Hypercoagulability: Congenital and Acquired Thrombophilias
- 1 January 1998
- journal article
- Published by SAGE Publications in Clinical and Applied Thrombosis/hemostasis
- Vol. 4 (1) , 25-50
- https://doi.org/10.1177/107602969800400106
Abstract
This article stresses the common hereditary and acquired blood protein defects associated with thrombosis. The most common of the hereditary defects apear to be APC-R, SPS, antithrombin, protein C, and protein S deficiency, and the most common acquired defects are anticardiolipin antibodies and the lupus anticoagulant (antiphospholipid antibodies). Therefore, these are the defects that should first be looked for in an individual with unexplained thrombosis. If these more common defects are not found, then the rarer defects including HC II, plasminogen or TPA deficiency, dysfibrinogenemia, el evated PAI-1 and hyperhomocysteinemia should be sought. The importance of finding these defects has significant impli cations for therapy of the individual patient and for institutions of family studies to identify, inform, and possibly treat others at risk. It is expected that as knowledge of hemostasis expands, more hereditary and acquired defects, such as elevated lipopro tein (a) or defects of extrinsic (tissue factor) pathway inhibitor (EPI, TFPI), may be associated with enhanced risks of throm bosis. Finally, it must be recalled that a diagnosis of thrombo sis, like that of anemia, is only a generic and partial diagnosis; just as in the anemic patient, the etiology must be clearly de fined. Only in this manner can cost-effective and appropriate therapy for both primary treatment and secondary prevention be designed. In addition, the demonstration of a hereditary defect will allow primary prevention in afflicted family mem bers by allowing the choice of appropriate therapy.Keywords
This publication has 223 references indexed in Scilit:
- Oral contraceptives and venous thrombosis: different sensitivities to activated protein C in women using second‐ and third‐generation oral contraceptivesBritish Journal of Haematology, 1997
- Mutation in blood coagulation factor V associated with resistance to activated protein CNature, 1994
- Hereditary thrombophilia among 217 consecutive patients with thromboembolic disease in JordanAmerican Journal of Hematology, 1993
- Incidence and clinical characteristics of hereditary disorders associated with venous thrombosisAmerican Journal of Hematology, 1991
- Platelet lipoxygenase defect (wien‐penzing defect) in two patients with myocardial infarctionAmerican Journal of Hematology, 1991
- Low protein s in essential thrombocythemia with thrombosisAmerican Journal of Hematology, 1989
- Heparin cofactor II in adults and infants with thrombosis and DICAmerican Journal of Hematology, 1989
- Platelet hyperaggregability in patients with chest pain and angiographically normal coronary arteriesThe American Journal of Cardiology, 1986
- ASSOCIATION OF HEREDITARY HEPARIN CO-FACTOR II DEFICIENCY WITH THROMBOSISThe Lancet, 1985
- Anticoagulant activity of heparin: Separation of high‐activity and low‐activity heparin species by affinity chromatography on immobilized antithrombinFEBS Letters, 1976